EUVIMEDEUVIMED entdecken
Crossref

Lipoprotein(a) levels across histological severity in metabolic dysfunction–associated steatotic liver disease

Gaetano Leo, Nicholas Cocomello, Diletta Oteri, Erika Paolino, Federica Moscucci, Vittoria Cammisotto, Daniele Pastori, Pasquale Pignatelli, Guido Carpino, Eugenio Gaudio, Giovambattista Desideri, Francesco Baratta

European Atherosclerosis Journal · 30.04.2026 · 5 (1) · 24

DOI: 10.56095/eaj.v5i1.134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Atherosclerosis Journal, online erschienen am 30.04.2026. Verfasst von Gaetano Leo und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction–associated steatotic liver disease (MASLD) encompasses a spectrum ranging from simple steatosis to metabolic dysfunction–associated steatohepatitis (MASH) and cirrhosis. Lipoprotein(a) [Lp(a)] is a well-established atherogenic risk factor, but its relationship with MASLD and its histological severity has been poorly investigated. The aim of this study was to describe plasma Lp(a) levels across different histological stages and features of MASLD.

Methods

Eighty-eight patients enrolled in the PLINIO study (ClinicalTrials.gov Identifier: NCT04036357) who underwent liver biopsy were included. Plasma Lp(a) levels were measured using a specific ELISA kit. Patients were stratified according to histological diagnosis into simple steatosis (MASLD-SS), MASH, and cirrhosis. In a subgroup of 29 patients, immunohistochemical analysis was performed to assess hepatic Lp(a) expression on liver biopsy samples.

Results

Plasma Lp(a) levels increased progressively with histological severity (MASLD-SS: 22.1 [20.2–26.6] mg/dL; MASH: 28.7 [24.2–32.8] mg/dL; cirrhosis: 31.1 [29.4–33.1] mg/dL; p=0.001). Plasma Lp(a) correlated positively with fibrosis stage (rS=0.401, p

Zitieren

APA

Leo, G., Cocomello, N., Oteri, D., Paolino, E., Moscucci, F., Cammisotto, V., Pastori, D., Pignatelli, P., Carpino, G., Gaudio, E., Desideri, G., & Baratta, F. (2026). Lipoprotein(a) levels across histological severity in metabolic dysfunction–associated steatotic liver disease. European Atherosclerosis Journal, 5(1), 24. https://doi.org/10.56095/eaj.v5i1.134

Vancouver

Leo G, Cocomello N, Oteri D, Paolino E, Moscucci F, Cammisotto V, et al. Lipoprotein(a) levels across histological severity in metabolic dysfunction–associated steatotic liver disease. European Atherosclerosis Journal. 2026;5(1):24. doi:10.56095/eaj.v5i1.134

BibTeX
@article{Leo2026,
  author = {Leo, Gaetano and Cocomello, Nicholas and Oteri, Diletta and Paolino, Erika and Moscucci, Federica and Cammisotto, Vittoria and Pastori, Daniele and Pignatelli, Pasquale and Carpino, Guido and Gaudio, Eugenio and Desideri, Giovambattista and Baratta, Francesco},
  title = {Lipoprotein(a) levels across histological severity in metabolic dysfunction–associated steatotic liver disease},
  journal = {European Atherosclerosis Journal},
  year = {2026},
  volume = {5},
  number = {1},
  pages = {24},
  doi = {10.56095/eaj.v5i1.134}
}
Kostenlos starten →